Compass Therapeutics Inc. CMPX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 1:35 PM EDT
2.44quote price arrow up+0.01 (+0.47%)
Volume
70,200
52 week range
1.25 - 5.92
Loading...
  • Open2.45
  • Day High2.49
  • Day Low2.30
  • Prev Close2.43
  • 52 Week High5.92
  • 52 Week High Date06/04/21
  • 52 Week Low1.25
  • 52 Week Low Date03/29/22

Key Stats

  • Market Cap247.12M
  • Shares Out101.28M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-21.45

KEY STATS

  • Open2.45
  • Day High2.49
  • Day Low2.30
  • Prev Close2.43
  • 52 Week High5.92
  • 52 Week High Date06/04/21
  • 52 Week Low1.25
  • 52 Week Low Date03/29/22
  • Market Cap247.12M
  • Shares Out101.28M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-21.45

RATIOS/PROFITABILITY

  • EPS (TTM)-1.39
  • P/E (TTM)-1.75
  • Fwd P/E (NTM)-5.74
  • EBITDA (TTM)-81.041M
  • ROE (TTM)-97.55%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Compass Therapeutics Inc.

There is no recent news for this security.

Profile

MORE
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing antibody-based therapeutics to treat multiple human diseases. Its pipeline of product candidates targets multiple critical biological pathways required for an anti-tumor response, which include modulation of the microvasculature via angiogenesis-targeted agents. Its clinical-stage product candidates include CTX-009 and CTX-471. CTX-009 is a...
Address
80 Guest Street
Boston, MA
02135
United States